WA
SUPN icon

WealthTrust Axiom’s Supernus Pharmaceuticals SUPN Stock Holding History

WealthTrust Axiom’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-17,500
Closed -$191K – 232
2014
Q2 		$191K Buy
+17,500
New +$156K 0.06% 199

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OHCM
Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WealthTrust Axiom's SUPN Position: Q3 2014 in Review

WealthTrust Axiom sold out of Supernus Pharmaceuticals (SUPN) in Q3 2014, closing a stake of 17,500 shares — an estimated $191K sold.

WealthTrust Axiom first reported a position in SUPN in Q2 2014 and held it in 1 quarter. The position peaked at $191K in Q2 2014. 93 funds tracked by Wall St. Rank hold SUPN as of Q3 2014.

  • WealthTrust Axiom reported no remaining Supernus Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • WealthTrust Axiom sold 17,500 Supernus Pharmaceuticals shares in Q3 2014, an estimated $191K.
  • WealthTrust Axiom first reported a position in Supernus Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • WealthTrust Axiom's Supernus Pharmaceuticals position peaked at $191K in Q2 2014.
  • 93 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2014.

Based on WealthTrust Axiom's 13F filing for Q3 2014, filed 5 Nov 2014.